We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Value Investors Pick Vertex Pharmaceuticals (VRTX) Stock?
Read MoreHide Full Article
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Vertex Pharmaceuticals Incorporated (VRTX - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Vertex Pharmaceuticals has a trailing twelve months PE ratio of 19.51, as you can see in the chart below:
Image Source: Zacks Investment Research
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 21.06. If we focus on the long-term PE trend, Vertex Pharmaceuticals’ current PE level puts it below its midpoint over the past three years. Moreover, the current level is fairly below the highs for this stock, suggesting it might be a good entry point.
Image Source: Zacks Investment Research
Further, the stock’s PE also compares favorably with the sector’s trailing twelve months PE ratio, which stands at 25.78. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
Image Source: Zacks Investment Research
We should also point out that Vertex Pharmaceuticals has a forward PE ratio (price relative to this year’s earnings) of just 16.03, so it is fair to say that a slightly more value-oriented path may be ahead for Vertex Pharmaceuticals stock in the near term too.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Vertex Pharmaceuticals has a P/S ratio of about 7.79. This is higher than the S&P 500 average, which comes in at 4.87 right now. However, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
Image Source: Zacks Investment Research
If anything, VRTX is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, Vertex Pharmaceuticals currently has a Zacks Value Style Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Vertex Pharmaceuticals a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for Vertex Pharmaceuticals is 1.03, a level that is lower than the industry average of 1.14. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Clearly, VRTX is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Vertex Pharmaceuticals might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of C and a Momentum score of C. This gives VRTX a Zacks VGM score—or its overarching fundamental grade—of C. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been encouraging. The current quarter has seen two estimates go higher in the past sixty days compared to one lower, while the full year estimate has seen eight upward and two downward revisions in the same time period
As a result, the current quarter consensus estimate has risen by 7.2% in the past two months, while the full year estimate has increased 7.6%.
This favorable trend is why the stock has a Zacks Rank #2 (Buy) and why we are looking for outperformance from the company in the near term.
Bottom Line
Vertex Pharmaceuticals is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Its strong Zacks Rank also indicates robust growth potential in the near future. However, the company’s prospects might be constrained due to adverse broader factors, as it has a sluggish industry rank (Bottom 42% out of more than 250 industries). In fact, over the past two years, the industry has clearly underperformed the broader market, as you can see below:
Image Source: Zacks Investment Research
So, value investors might want to wait for the broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Should Value Investors Pick Vertex Pharmaceuticals (VRTX) Stock?
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Vertex Pharmaceuticals Incorporated (VRTX - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Vertex Pharmaceuticals has a trailing twelve months PE ratio of 19.51, as you can see in the chart below:
Image Source: Zacks Investment Research
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 21.06. If we focus on the long-term PE trend, Vertex Pharmaceuticals’ current PE level puts it below its midpoint over the past three years. Moreover, the current level is fairly below the highs for this stock, suggesting it might be a good entry point.
Image Source: Zacks Investment Research
Further, the stock’s PE also compares favorably with the sector’s trailing twelve months PE ratio, which stands at 25.78. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
Image Source: Zacks Investment Research
We should also point out that Vertex Pharmaceuticals has a forward PE ratio (price relative to this year’s earnings) of just 16.03, so it is fair to say that a slightly more value-oriented path may be ahead for Vertex Pharmaceuticals stock in the near term too.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Vertex Pharmaceuticals has a P/S ratio of about 7.79. This is higher than the S&P 500 average, which comes in at 4.87 right now. However, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
Image Source: Zacks Investment Research
If anything, VRTX is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, Vertex Pharmaceuticals currently has a Zacks Value Style Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Vertex Pharmaceuticals a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for Vertex Pharmaceuticals is 1.03, a level that is lower than the industry average of 1.14. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Clearly, VRTX is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Vertex Pharmaceuticals might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of C and a Momentum score of C. This gives VRTX a Zacks VGM score—or its overarching fundamental grade—of C. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been encouraging. The current quarter has seen two estimates go higher in the past sixty days compared to one lower, while the full year estimate has seen eight upward and two downward revisions in the same time period
As a result, the current quarter consensus estimate has risen by 7.2% in the past two months, while the full year estimate has increased 7.6%.
This favorable trend is why the stock has a Zacks Rank #2 (Buy) and why we are looking for outperformance from the company in the near term.
Bottom Line
Vertex Pharmaceuticals is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Its strong Zacks Rank also indicates robust growth potential in the near future. However, the company’s prospects might be constrained due to adverse broader factors, as it has a sluggish industry rank (Bottom 42% out of more than 250 industries). In fact, over the past two years, the industry has clearly underperformed the broader market, as you can see below:
Image Source: Zacks Investment Research
So, value investors might want to wait for the broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.